CLINICAL TRIALS PROFILE FOR EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

All Clinical Trials for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02353676 ↗	Bupivacaine Supplementation For Postoperative Pain Control In Surgical Removal Of Mandibular Third Molars	Unknown status	Cosmozone Dental Clinic	N/A	2015-01-01	Control of postoperative pain is a foremost goal in achieving a satisfactory postoperative recovery. Surgical removal of lower third molars is accompanied by postoperative pain that is at its peak in the first 12 hours. Our study evaluates if the use of 2% lidocaine hydrochloride for the surgical removal of lower third molars with a postoperative 0.5% bupivacaine supplementation would result in lesser postoperative pain and a decrease in ingestion of oral analgesics to control the pain when compared to a placebo.
NCT03672500 ↗	Perineal Local Infiltration Study	Recruiting	Sunnybrook Health Sciences Centre	N/A	2018-09-14	The prevalence of birth canal lacerations is more than 70% of all deliveries in Canada. The repair of such lacerations is usually done using a pre-existing epidural analgesia. Once the analgesic effect of the epidural analgesia fades, the laceration may cause intolerable pain, and result in emotional stress, difficulties in ambulation and breastfeeding, and more. The research team hypothesis is that adding a locally injected analgesic, which will take effect once the epidural analgesia fades, may alleviate perineal pain, prevent such difficulties, and improve women's overall well-being and satisfaction. The proposed trial is a two-arm, single-masked, randomized trial. Women with a working epidural analgesia, and a laceration will be invited to participate. Women in the local anesthesia (LA) arm will get a LA injected to the laceration and women in the sham arm will get no injection. The differences in perineal pain between the groups will be evaluated at 6 hours after last epidural dose.
NCT05152901 ↗	Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults	Not yet recruiting	Novotech (Australia) Pty Limited	Phase 1	2022-01-23	This is a study to determine the relative bioavailability of inhaled epinephrine compared with 0.3mg epinephrine administered IM in healthy male and female participants.
NCT05152901 ↗	Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults	Not yet recruiting	De Motu Cordis	Phase 1	2022-01-23	This is a study to determine the relative bioavailability of inhaled epinephrine compared with 0.3mg epinephrine administered IM in healthy male and female participants.

Clinical Trial Conditions for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Condition Name

Condition Name for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Intervention	Trials
Anesthesia, Local	2
Pain	1
Second Degree Perineal Tear During Delivery - Delivered	1
Trauma, Multiple	1

Condition MeSH

Condition MeSH for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Intervention	Trials
Pain	1
Wounds and Injuries	1
Multiple Trauma	1
Anaphylaxis	1

Clinical Trial Locations for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Trials by Country

Trials by Country for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Location	Trials
Thailand	1
Australia	1
Canada	1
Saudi Arabia	1

Clinical Trial Progress for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1
COMPLETED	1

Clinical Trial Sponsors for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Sponsor Name

Sponsor Name for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Sponsor	Trials
De Motu Cordis	1
Siriraj Hospital	1
Visarat Palitnonkiat	1

Sponsor Type

Sponsor Type for EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Sponsor	Trials
Other	5
Industry	2

Epinephrine Bitartrate in 0.9% Sodium Chloride: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 30, 2026

What is the product and how is it positioned clinically?

Epinephrine bitartrate in 0.9% sodium chloride is an injectable epinephrine formulation delivered in 0.9% NaCl as the diluent. In clinical practice, epinephrine is used for acute, life-threatening allergic reactions (anaphylaxis) and for certain emergency cardiopulmonary indications, with use patterns shaped by dosing protocols, availability of prefilled epinephrine formats, and guideline-driven administration in emergency settings.

Across major markets, epinephrine injection demand is influenced more by:

• Emergency department and pre-hospital care protocols (formulary access and stocking decisions)
• Competitive pressure from auto-injectors and other epinephrine injection formats
• National procurement cycles and tender dynamics

What is the clinical trials landscape update?

No complete, verifiable, up-to-date clinical trials dataset specific to epinephrine bitartrate in 0.9% sodium chloride is available in the provided information. Under this constraint, a trials update cannot be produced without risking inaccuracies (trial existence, phases, enrollment, and timelines are product- and salt- and presentation-specific).

How big is the market today and what drives demand?

A precise market size for this specific presentation (epinephrine bitartrate + 0.9% NaCl) cannot be calculated from the provided information. Market reporting for epinephrine products is usually aggregated across presentations (vials, prefilled syringes, auto-injectors) and across formulations (different salts and concentrations).

What can be stated as the demand drivers that shape commercial outcomes for this presentation type:

Demand drivers

• Acute use economics: Epinephrine is purchased in emergency-ready quantities; conversion is driven by government and hospital procurement cadence.
• Guideline administration: Anaphylaxis protocols push epinephrine use, with institutional preference for formats that support rapid administration.
• Formulary access and tender terms: Public procurement often favors lowest cost per dose while maintaining stock continuity.
• Competitive substitution: Auto-injectors substitute for some outpatient and community use; hospitals may still stock vials/prefilled products for broader dosing control in ER and inpatient settings.
• Supply continuity risk management: Hospitals prioritize suppliers with reliable distribution for emergency stock.

Competitive map (product-type level)

While exact competitors for this exact presentation cannot be enumerated without a complete dataset, market competition for epinephrine injection typically includes:

• Generic epinephrine injection vials and prefilled syringes
• Brand epinephrine products in certain geographies
• Auto-injector products for community settings (different customer segment and reimbursement dynamics)

What is the revenue model and what should be monitored?

For this class of product, commercialization usually follows:

• Institutional sales (hospitals, emergency services, public health stock programs)
• Tender-based contracting with fixed quantities and substitution clauses
• Shelf life and handling as procurement filters (cold chain requirements if any, stability claims, and labeling that matches local emergency protocols)
• Price pressure from generic competition and periodic tender repricing

Commercial KPIs used by buyers

• Cost per administered dose (not just list price)
• Availability and delivery reliability
• Number of doses per unit and dosing flexibility
• Regulatory and pharmacovigilance record in the local market

What is the near- to mid-term market projection?

A numeric projection for epinephrine bitartrate in 0.9% sodium chloride cannot be produced from the information available in the prompt. Any quantitative forecast would require product-specific historical sales, geography splits, and trial or launch timelines that are not provided.

Where does value concentrate across the product lifecycle?

Even without a quantified forecast, the value concentration for this presentation typically occurs around:

• Tender cycles in public and large hospital networks
• Switching events driven by procurement renegotiations, pharmacy formulary updates, or substitution policies
• Regulatory or label updates that affect dosing language and emergency administration protocols

Actionable business implications for R&D and investment

Given the need to keep the analysis product-specific and the absence of trials and commercial data for this exact presentation in the provided information, the actionable path for decision-makers is limited to framework-level observations that consistently determine outcomes for emergency injectable products:

• Differentiate on supply and contracting execution: For tender-driven categories, distribution reliability and contract compliance drive share as much as marketing.
• Map substitution risk: Auto-injectors may reduce some outpatient demand, but they often do not eliminate institutional need for injectable epinephrine in ER and inpatient care.
• Plan for price erosion typical of generics: Budget for repricing and maintain margins through manufacturing cost control and contract renewal strategy.
• Align with protocol dosing needs: Buyers prefer presentations that match emergency administration workflows (vial vs prefilled, concentration, and ease of use).

---

Key Takeaways

• A product-specific clinical trials update cannot be completed from the information provided; the required product-level dataset is not available here.
• A product-specific market size and numeric projection cannot be produced without sales history and geography-level data for this exact formulation and presentation.
• Commercial outcomes for epinephrine injection presentations are mainly driven by emergency procurement cycles, tender economics, formulary access, and substitution effects from other epinephrine formats.

FAQs

1. Is epinephrine bitartrate in 0.9% sodium chloride used for anaphylaxis?
   Yes. Epinephrine injection products are used for anaphylaxis per emergency treatment protocols, with dosing and route managed by clinical setting and formulation availability.

2. Does anaphylaxis demand translate equally across all epinephrine presentations?
   No. Demand varies by setting. Hospitals and ERs often rely on injectable vials or prefilled formats, while community care uses auto-injectors more frequently.

3. What determines procurement share for emergency injectable epinephrine products?
   Tender terms, cost per dose, supply reliability, and the match to local emergency dosing workflows.

4. How does generic competition affect this category?
   Price compression is common after market entry of multiple approved products, with share increasingly determined by contracting and supply continuity.

5. Can clinical outcomes data replace market sizing for investment decisions?
   Not on its own. For tender-driven injectable products, market share and margin depend on procurement and contracting dynamics, not just clinical efficacy.

---

References

[1] No sources were provided in the prompt.